The CNS disorders have been increasing and so is the need for treatments. Biomarkers are medical signs or objective indications of a medical state observed from outside the patient, measured accurately and reproducibly. The CNS biomarkers are used to detect and identify the state of a CNS disease, like the Parkinson's disease.
The high investment in proteomics and genomics research and the need for cost-efficient solutions to treat CNS disorders are the major factors accelerating the market growth. However, there are certain factors that are hindering the market growth, which include high cost of CNS biomarker test & diagnostics and certain issues related to regulatory and reimbursement systems.
The global market is segmented based on application, end-users and geography. The North American market for CNS biomarkers is expected to hold the largest share, globally, due to the rapid use of various cardiac biomarkers combinations.
Some of the major players in this market are:
Thermo Fisher Scientific
Merck & Co.
AbaStar MDx Inc
Avacta group plc
Market analysis, with region-specific assessments and competition analysis on a global and regional scale.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, growing prospective opportunities, and identification of key companies that can influence the market.
Extensively researched competitive landscape section with profiles of major companies, along with their market share.
Identification and analysis of the macro and micro factors that affect the market on both, global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-range of knowledge and insights about the major players in the industry and the key strategies adopted by them to sustain and grow in the studied market
Insights on the major countries/regions where the industry is growing, and identify the regions that are still untapped.
1.1 Market Definition
1.2 Research Methodology
2. Executive Summary
3. Key Inferences
4. Market Overview
4.1 Current Market Scenario
4.2 Porter's Five Forces Analysis
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Consumers
4.2.3 Threat of New Entrants
4.2.4 Threat of Substitute Products and Services
4.2.5 Competitive Rivalry within the Industry
5. Drivers, Restraints, Opportunities & Challenges Analysis (DROC)
5.1 Market Drivers
5.1.1 Development in Proteomics and Genomics has led to Discovery of Novel Biomarkers.
5.1.2 Funding from Government and Private Players to boost CNS Biomarker Market
5.2 Market Restraints
5.2.1 High Cost of CNS Biomarker Test and Diagnostics
5.2.2 Issues Related to Regulatory and Reimbursement Systems
5.3 Market Opportunities
5.3.1 Increased demand for personalised medicine
5.4 Market Challenges
6. Types of CNS Biomarker
6.1 Safety Biomarker
6.2 Efficacy Biomarker
6.2.1 Pharmacodynamic Biomarker
6.2.2 Predictive Biomarker
6.2.3 Prognostic Biomarker
6.3 Validation Biomarker
7. Market Segmentation
7.1 Market Segmentation by Application
7.1.1 Drug Discovery & Development
7.1.2 Personalized Medicine
7.1.3 Disease Risk Assessment
7.2 Market Segmentation By End User
7.2.1 Diagnostic Labs
7.2.2 Outpatient Clinics
7.2.3 Research Centers
7.3 Market Segmentation By Geography
7.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kigdom
184.108.40.206 Rest of Europe
220.127.116.11 Rest of APAC
7.3.4 Middle East and Africa
18.104.22.168 South Africa
7.3.5 South America
22.214.171.124 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisitions
8.2 Partnerships, Collaborations and Agreements
8.3 New Product Launches
9. Company Profiles
9.1 Abastar Mdx, Inc.
9.2 Thermo Fisher Scientific
9.3 Abiant, Inc.
9.4 Merck & Co., Inc.
9.5 Diagenic Asa
9.6 Banyan Biomarkers
9.7 Avid Radiopharmaceuticals Inc.
9.8 Avacta Group Plc
10. Future Market Scenario